Author + information
- Received April 2, 2014
- Revision received May 27, 2014
- Accepted May 28, 2014
- Published online August 5, 2014.
- ∗Department of Medicine, Division of Cardiology, University of California San Diego, San Diego, California
- †Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, Texas
- ↵∗Reprint requests and correspondence:
Dr. Eric D. Adler, University of California San Diego, 9300 Campus Point Drive #7411, La Jolla, California.
Groundbreaking advances in stem cell research have led to techniques for the creation of human cardiomyocytes from cells procured from a variety of sources, including a simple skin biopsy. Since the advent of this technology, most research has focused on utilizing these cells for therapeutic purposes. However, recent studies have demonstrated that stem cell–derived cardiomyocytes generated from patients with inherited cardiovascular disorders recapitulate key phenotypic features of disease in vitro. Furthermore, these cells can be maintained in culture for prolonged periods of time and used for extensive biochemical and physiological analysis. By serving as models of inherited cardiac disorders, these systems have the potential to fundamentally change the manner in which cardiovascular disease is studied and new therapies are developed.
All authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received April 2, 2014.
- Revision received May 27, 2014.
- Accepted May 28, 2014.
- American College of Cardiology Foundation